share_log

研报掘金丨国盛证券：片仔癀推动建设新产品矩阵，维持“买入”评级

Research reports Jincheng | Guosheng Securities: Zhangzhou Pientzehuang Pharmaceutical promotes the construction of a new product matrix, maintaining a buy rating.

Gelonghui Finance ·  Jul 30 03:29

国盛证券研报指出，片仔癀(600436.SH)成本端短期承压，核心产品稳步增长且产品矩阵有望逐步丰富，维持“买入”评级。第二季度实现归母净利润7.45亿元，同比下滑3.4%。受重要原材料成本上涨影响，公司利润端略承压，未来公司积极做好相关原材料战略储备，提前布局以控制成本端影响。公司推动建设新产品矩阵，驱动营销环节新活力，打造销售增长新引擎，助力实现片仔癀牌安宫牛黄丸、茵胆平肝胶囊、复方片仔癀含片、肝宝四个单品种过亿，打造珍珠霜、珍珠膏和美白祛斑膏等多款销售过亿单品。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment